Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
crawled time : 20:20 save search
Alaska Airlines and Hawaiian Airlines to Combine, Expanding Benefits and Choice for Travelers Throughout Hawai'i and the West Coast
Published: 2023-12-03 (Crawled : 20:20) - prnewswire.com
ALK | $44.44 4.03% -0.27% 5.6M
|
Transportation
|
| O: -15.25%
H: 1.81%
C: 1.22%
HA | $12.99 -1.96% -2.0% 2.3M
|
Transportation
|
| O: 179.63%
H: 4.86%
C: 4.64%
airlines west choice benefits
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
Published: 2023-01-08 (Crawled : 20:20) - globenewswire.com
MC | News | $50.97 -0.57% 0.0% 370K
|
Finance
|
| O: 0.09%
H: 2.68%
C: 0.85%
AMYT | $14.7 0.0% 2.4M
|
Health Technology
|
| O: 106.53%
H: 0.0%
C: 0.0%
pharma acquire
RAPT Therapeutics to Report Top Line Data from Phase 1b Trial of RPT193 in Atopic Dermatitis
Published: 2021-06-13 (Crawled : 20:20) - globenewswire.com
RAPT | $7.94 -1.24% -1.26% 710K
|
Health Technology
|
| O: 56.92%
H: 44.1%
C: 37.34%
phase 1 dermatitis trial topline atopic dermatitis phase 1b phase 2b
Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis
Published: 2023-01-22 (Crawled : 20:20) - globenewswire.com
PLRX | $12.23 -4.9% -5.15% 360K
|
Health Technology
|
| O: 55.66%
H: 4.17%
C: -13.58%
fibrosis trial therapeutics positive phase 2b
Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
Published: 2024-01-07 (Crawled : 20:20) - globenewswire.com
VINC | $0.8967 -5.63% -5.97% 530K
|
|
| O: 38.56%
H: 4.59%
C: -16.82%
pharma
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
Published: 2023-11-05 (Crawled : 20:20) - globenewswire.com
CLDX | News | $38.49 -2.88% -2.96% 580K
|
Health Technology
|
| O: 26.94%
H: 1.73%
C: -11.01%
positive skin therapeutics study
Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT: 100% Overall Response Rate in DARZALEX-Relapsed/Refractory AL Amyloidosis with Zero ICANs in Ongoing NEXICART-1 Phase 1b/2a Clinical Trial
Published: 2023-05-21 (Crawled : 20:20) - globenewswire.com
IMMX | $2.25 -10.0% -11.11% 190K
|
|
| O: 17.68%
H: 0.0%
C: -9.33%
nxc-201 positive biopharma ongoing trial response results
Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives
Published: 2023-01-08 (Crawled : 20:20) - globenewswire.com
VIRX | $0.8971 -4.18% -4.36% 79K
|
Manufacturing
|
| O: 17.07%
H: 8.33%
C: 5.21%
tumor therapeutics response
Technicolor Creative Studios: Conditions of availability of information prepared in connection with the Combined Shareholders’ Meeting to be held May 15, 2023
Published: 2023-04-23 (Crawled : 20:20) - globenewswire.com
TCLRY | $0.001 1000.0% 140K
|
Manufacturing
|
| O: 15.52%
H: 0.0%
C: -16.42%
meeting
Technicolor Creative Studios: 2022 Universal Registration Document Available
Published: 2023-04-23 (Crawled : 20:20) - globenewswire.com
TCLRY | $0.001 1000.0% 140K
|
Manufacturing
|
| O: 15.52%
H: 0.0%
C: -16.42%
universal
The Cigna Group Announces Significant Increase to Share Repurchase Program of $10 Billion
Published: 2023-12-10 (Crawled : 20:20) - prnewswire.com
CI | $348.78 0.78% 0.0% 1.6M
|
Health Services
|
| O: 15.46%
H: 1.63%
C: 1.05%
group repurchase program
Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference
Published: 2023-01-08 (Crawled : 20:20) - globenewswire.com
MOLN | News | $3.67 -3.42% -3.54% 320
|
Professional, Scientific, and T...
|
| O: 11.94%
H: 1.06%
C: -0.92%
conference molecular
Attention Futu Holdings Limited (FUTU) Shareholders: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Securities Fraud Class Action Lawsuit Filed against Futu Holdings Limited and Encourages Investors With Significant Losses to Contact the Firm
Published: 2023-07-09 (Crawled : 20:20) - prnewswire.com
CRL | $227.55 -1.1% 0.0% 710K
|
Commercial Services
|
| O: -1.93%
H: 3.54%
C: 2.91%
IEP | $16.89 -0.71% -0.71% 370K
|
Producer Manufacturing
|
| O: 10.22%
H: 10.97%
C: 9.05%
FUTU | $54.87 0.99% 0.98% 790K
|
Technology Services
|
| O: -0.8%
H: 2.55%
C: 1.48%
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
Published: 2024-04-07 (Crawled : 20:20) - globenewswire.com
ESPR | $1.865 1.36% 1.34% 6M
|
Health Technology
|
| O: 9.32%
H: 0.0%
C: -10.88%
nexletol obesity
Zepp Health Unveils Zepp OS 3.5 with Zepp Flow™, Powered by Large Language Model AI, Pioneering the Next Generation of Wearable Intelligence Devices at MWC Barcelona 2024
Published: 2024-02-25 (Crawled : 20:20) - prnewswire.com
ZEPP | $0.8465 2.53% 1.21% 62K
|
Manufacturing
|
| O: 8.47%
H: 0.0%
C: -7.03%
intelligence health
BURFORD CAPITAL STATEMENT ON YPF SUMMARY JUDGMENT RULING
Published: 2023-04-02 (Crawled : 20:20) - prnewswire.com
BUR | $14.86 -1.33% -2.09% 1.7M
|
Finance
|
| O: 8.23%
H: 0.42%
C: -7.6%
Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism
Published: 2022-05-01 (Crawled : 20:20) - globenewswire.com
RZLT 4 | $3.305 2.01% 1.97% 280K
|
Technology Services
|
| O: 6.72%
H: 2.1%
C: 1.05%
rz358 positive phase 2b
IGC Form 10-Q
Published: 2022-08-07 (Crawled : 20:20) - igcinc.us
IGC 4 | $0.4761 -18.82% -1.28% 1.3M
|
Health Technology
|
| O: 5.47%
H: 1.72%
C: 0.0%
Global Algae Product Market Analysis Report 2022: Focus on Spirulina, Chlorella, Astaxanthin, Beta-carotene, & Hydrocolloids - Forecast to 2028
Published: 2023-01-22 (Crawled : 20:20) - prnewswire.com
CYAN | $0.33 -0.03% 38K
|
Health Technology
|
| O: 5.26%
H: 0.0%
C: -1.67%
global report market
Affimed Presents Final Data Demonstrating Safety and Efficacy of AFM13 Phase 2 REDIRECT Study in Patients with Heavily Pretreated Relapsed or Refractory Peripheral T Cell Lymphoma at the American Association for Cancer Research Annual Meeting 2023
Published: 2023-04-16 (Crawled : 20:20) - globenewswire.com
AFMD | News | $5.1 -2.49% -2.55% 90K
|
Health Technology
|
| O: 4.71%
H: 5.81%
C: 2.93%
afm13 association cancer cell research meeting study
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.